By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
LSN is excited to announce Genaxis, a leading South Korea based accelerator and early-stage fund dedicated to deeptech and biotech innovation, as a Silver Sponsor of RESI Boston.
Genaxis is bringing five of Korea’s most innovative biotech and medtech startups to the global stage. These companies will be pitching at RESI Boston on September 17, 2025, where they will showcase breakthrough solutions spanning therapeutics, medical devices, digital health, and enabling technologies.
To provide an additional opportunity for investor engagement, Genaxis will also host an exclusive pre-RESI pitch session the day before the conference. The event will take place on Tuesday, September 16, 2025, 9:00 – 11:00am EST, at CIC Boston (50 Milk St, Boston, MA 02109).
At this session, 5 startups will each deliver a 6-minute pitch followed by a 7-minute Q&A, and active investors and strategic partners are invited to join. Please RSVP below if you are interested in meeting Genaxis and the pitching companies. Brief descriptions are provided below:
Bilix, Inc. is a biotechnology company dedicated to developing innovative therapies for intractable diseases in inflammation and cancer, with the mission to improve human health one patient at a time for better and longer lives. Driven by courage and determination, Bilix takes on the challenge of finding cures for conditions long considered incurable. Our goal is to expedite drug development and provide therapeutic answers for patients in urgent need, while upholding a commitment to fairness and accessibility. By delivering cost-effective, equitable treatment solutions, Bilix strives to transform the lives of patients worldwide and bring hope where few options exist.
DeepsonBio is a company specialized in ultrasound devices for treating dementia. By utilizing a non-invasive method, we offer a safe and highly effective treatment for patients with Alzheimer’s dementia and normal pressure hydrocephalus dementia.
Our therapeutic ultrasound device is designed to improve cognitive function in patients with mild cognitive impairment (MCI) and early-stage Alzheimer’s disease, utilizing Multiple Low Intensity Pliant Ultrasound (M-LIPUS) for cerebrofluid stimulation.
Main Business Area:
- Neurology
- Neurodegenerative disease
- Alzheimer’s disease
- Normal pressure hydrocephalus
EXOSYSTEMS Inc. is a South Korea–based digital health company pioneering AI-driven neuromuscular biomarkers to transform how motor function is assessed, diagnosed, and monitored. Founded in 2017 as a spin-out from ETRI, EXOSYSTEMS develops integrated solutions that combine clinical-grade EMG/IMU sensors with advanced AI analytics to deliver objective, quantitative insights into muscle and motor performance.
Its flagship technologies include the Muscle Function Index (MFI), a digital biomarker platform designed to replace fragmented and subjective in-person motor assessments with standardized, high-resolution measures. These solutions serve both pharmaceutical companies, by providing validated digital endpoints for clinical trials, and hospitals and clinics, by enabling efficient point-of-care diagnostics and patient monitoring.
With $4M secured in VC funding, over $10M in national R&D grants, regulatory recognition from the Korean FDA, and validation studies with Roche Korea, EXOSYSTEMS is positioned to set a new global standard for neuromuscular digital health.
Laon Medi is a digital health company transforming orthodontics with software-driven workflows. Our flagship platform, Laon Ortho, solves the inefficiencies of clear aligner treatment planning, a process that traditionally requires hours of manual work and outsourced lab services. By automating case setup and integrating multimodal data such as CBCT and intraoral scans, Laon Ortho reduces planning time to minutes while allowing clinics to manage cases in-house. This shift improves margins, lowers patient costs, and accelerates adoption of clear aligner therapy. Laon Ortho is commercially deployed in dozens of clinics and labs across Korea, generating post-pilot revenues and validating scalability. The company is now expanding globally with a model that serves clinics, labs, and DSOs, positioning itself as a scalable digital dentistry platform with clear cost advantages and growing international demand.
RadaHaim, founded in 2022, is a biotechnology company pioneering standardized, scalable organoid platforms for drug discovery and toxicology testing. We have developed patient-derived and iPSC-derived liver organoids with consistent size and morphology, enabling reliable disease modeling and drug-induced liver injury (DILI) assays. Our preclinical service platform operates under GLP-inspired workflows, including batch-level QC, reference compound benchmarking, and high-content imaging analytics. By bridging the translational gap between animal studies and clinical outcomes, RadaHaim provides pharmaceutical and biotech partners with more predictive data to accelerate drug development and reduce failures in clinical trials. In addition to CRO services, our long-term goal is to commercialize assay kits that integrate standardized organoids with ready-to-use protocols. Based in Korea and now expanding into the U.S., RadaHaim aims to become a global leader in organoid-based NAMs (New Approach Methodologies) aligned with regulatory acceptance and the future of animal-free testing.
About Genaxis:
Genaxis is a leading accelerator dedicated to supporting deep-tech and biotech startups. We deliver customized acceleration programs, strategic mentoring, and global investor access to help companies grow beyond their local markets. With expertise in investment readiness, cross-border collaboration, and global market entry, Genaxis equips entrepreneurs with the tools and networks they need for sustainable growth. As a Silver Sponsor of RESI Boston 2025, we are committed to connecting innovative startups with global life science investors, fostering collaboration between Korea and the world. Our mission is to empower founders to achieve impactful innovation, create long-term value, and strengthen the global startup ecosystem.
Tags: business, entrepreneurship, finance, health, Healthcare, investing, startups, technology, venture capital
The official program guide for RESI Boston, September 2025 is now available! Redefining Every Stage of Investment (RESI) is designed to connect life science and healthcare innovators with a global network of investors across diverse funding strategies, from Seed through Series B and beyond.
For biotech founders, intellectual property (IP) can make or break a company. The life sciences industry is driven by innovation, but it is also crowded with patents. While it’s essential to build your own IP portfolio, it is just as critical to ensure that your product will not infringe on someone else’s. Overlooking this risk can expose your startup to costly lawsuits that could derail your business before it has a chance to grow.
Next Phase Newsletter 